New mRNA vaccine targets RSV in first human trial
NCT ID NCT06573281
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 23 times
Summary
This early-stage study tests an experimental mRNA vaccine designed to protect against respiratory syncytial virus (RSV). Around 213 healthy adults aged 18-45 will receive different doses of the vaccine or a placebo. The main goal is to check for side effects and measure the immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Rolling Hills Estates, California, 90274, United States
-
GSK Investigational Site
Atlanta, Georgia, 30281, United States
-
GSK Investigational Site
Lenexa, Kansas, 66219, United States
-
GSK Investigational Site
Omaha, Nebraska, 68134, United States
-
GSK Investigational Site
Rochester, New York, 14609, United States
-
GSK Investigational Site
Camberwell, Victoria, 3124, Australia
-
GSK Investigational Site
Madrid, 28006, Spain
-
GSK Investigational Site
Madrid, 28046, Spain
-
GSK Investigational Site
Madrid, 28222, Spain
Conditions
Explore the condition pages connected to this study.